Is Inhibikase Therapeutics Inc (IKT) overvalued? · $215.2M cap
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
This page asks whether Inhibikase Therapeutics Inc (IKT) looks expensive on cached numbers — not a short thesis.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
IKT currently screens at market cap $215.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IKT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IKT stock page for the full model, not this heading.
Not investment advice.